Rovalpituzumab tesirine and DLL3: a new challenge for small-cell lung cancer
Archived tumour tissue was available for 48 patients only, and the 50% cutoff used to define high or low expression of DLL3 was established post-hoc. [...]the biomarker analysis should be interpreted with great caution..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
The lancet |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rossi, Antonio [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: | |
|---|---|
| Themen: |
Biomarkers |
| doi: |
10.1016/S1470-2045(16)30575-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC198980375X |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC198980375X | ||
| 003 | DE-627 | ||
| 005 | 20230513152632.0 | ||
| 007 | tu | ||
| 008 | 170207s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(16)30575-7 |2 doi | |
| 028 | 5 | 2 | |a PQ20170301 |
| 035 | |a (DE-627)OLC198980375X | ||
| 035 | |a (DE-599)GBVOLC198980375X | ||
| 035 | |a (PRQ)c1270-ee30691de4c833cf86594a088b3287efbbae2bf7b7801d803349dda9337a367d0 | ||
| 035 | |a (KEY)0442821820170000018000100003rovalpituzumabtesirineanddll3anewchallengeforsmall | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 084 | |a 44.81 |2 bkl | ||
| 100 | 1 | |a Rossi, Antonio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rovalpituzumab tesirine and DLL3: a new challenge for small-cell lung cancer |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Archived tumour tissue was available for 48 patients only, and the 50% cutoff used to define high or low expression of DLL3 was established post-hoc. [...]the biomarker analysis should be interpreted with great caution. | ||
| 650 | 4 | |a Genes | |
| 650 | 4 | |a Cancer therapies | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Disease control | |
| 650 | 4 | |a Pharmaceutical industry | |
| 650 | 4 | |a Medical prognosis | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Lung cancer | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet <London> / Oncology |d Oxford : Elsevier, 2000 |g 18(2017), 1, Seite 3-5 |w (DE-627)330613073 |w (DE-600)2049730-1 |w (DE-576)100517625 |x 1470-2045 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2017 |g number:1 |g pages:3-5 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/S1470-2045(16)30575-7 |3 Volltext |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1855310353 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.81 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 18 |j 2017 |e 1 |h 3-5 | ||